{
  "id": "cha2ds2_vasc",
  "title": "CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk",
  "description": "Calculates the risk of stroke in patients with non-valvular atrial fibrillation, aiding in the decision regarding oral anticoagulation",
  "category": "cardiology",
  "version": "2010",
  "parameters": [
    {
      "name": "age",
      "type": "integer",
      "required": true,
      "description": "Patient's age in years",
      "validation": {
        "min": 18,
        "max": 120
      },
      "unit": "years"
    },
    {
      "name": "sex",
      "type": "string",
      "required": true,
      "description": "Patient's biological sex",
      "options": ["male", "female"],
      "validation": {
        "enum": ["male", "female"]
      }
    },
    {
      "name": "congestive_heart_failure",
      "type": "boolean",
      "required": true,
      "description": "History of congestive heart failure or left ventricular dysfunction (LVEF ≤40%)"
    },
    {
      "name": "hypertension",
      "type": "boolean",
      "required": true,
      "description": "History of arterial hypertension"
    },
    {
      "name": "stroke_tia_thromboembolism",
      "type": "boolean",
      "required": true,
      "description": "Previous history of stroke, TIA (transient ischemic attack) or thromboembolism"
    },
    {
      "name": "vascular_disease",
      "type": "boolean",
      "required": true,
      "description": "Vascular disease (previous myocardial infarction, peripheral artery disease or aortic plaque)"
    },
    {
      "name": "diabetes",
      "type": "boolean",
      "required": true,
      "description": "History of diabetes mellitus"
    }
  ],
  "result": {
    "name": "cha2ds2_vasc_score",
    "type": "integer",
    "unit": "points",
    "description": "Total CHA₂DS₂-VASc score (0-9 points)"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0,
        "max": 0,
        "stage": "Very Low Risk",
        "description": "Annual stroke risk: 0.3%",
        "interpretation": "Male patients with 0 points: anticoagulation not recommended. Consider aspirin or no antithrombotic therapy."
      },
      {
        "min": 1,
        "max": 1,
        "stage": "Low Risk",
        "description": "Annual stroke risk: 0.9%",
        "interpretation": "Men with 1 point: anticoagulation may be considered. Women with 1 point (due to sex only): anticoagulation not recommended."
      },
      {
        "min": 2,
        "max": 2,
        "stage": "Moderate Risk",
        "description": "Annual stroke risk: 2.9%",
        "interpretation": "Oral anticoagulation recommended (warfarin with INR 2-3 or DOAC). Benefit outweighs bleeding risk in most patients."
      },
      {
        "min": 3,
        "max": 3,
        "stage": "Moderate-High Risk",
        "description": "Annual stroke risk: 4.6%",
        "interpretation": "Oral anticoagulation strongly recommended. Consider DOACs as first choice due to better safety profile."
      },
      {
        "min": 4,
        "max": 4,
        "stage": "High Risk",
        "description": "Annual stroke risk: 6.7%",
        "interpretation": "Oral anticoagulation essential. Monitor adherence and adjust dose according to renal function if using DOACs."
      },
      {
        "min": 5,
        "max": 5,
        "stage": "High Risk",
        "description": "Annual stroke risk: 10.0%",
        "interpretation": "Oral anticoagulation mandatory. Consider strategies to improve adherence and minimize bleeding risk."
      },
      {
        "min": 6,
        "max": 6,
        "stage": "Very High Risk",
        "description": "Annual stroke risk: 13.6%",
        "interpretation": "Oral anticoagulation imperative. Evaluate and optimize modifiable risk factors. Frequent monitoring."
      },
      {
        "min": 7,
        "max": 9,
        "stage": "Extreme Risk",
        "description": "Annual stroke risk: >15%",
        "interpretation": "Critical oral anticoagulation. Consider left atrial appendage occlusion if absolute contraindication to anticoagulation."
      }
    ]
  },
  "references": [
    "Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.",
    "January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140(2):e125-e151.",
    "Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498."
  ],
  "formula": "CHA₂DS₂-VASc = C + H + A₂ + D + S₂ + V + A + Sc",
  "notes": [
    "C = Congestive heart failure (1 point)",
    "H = Hypertension (1 point)",
    "A₂ = Age ≥75 years (2 points), 65-74 years (1 point)",
    "D = Diabetes (1 point)",
    "S₂ = Previous Stroke/TIA/TE (2 points)",
    "V = Vascular disease (1 point)",
    "A = Age 65-74 years (1 point)",
    "Sc = Sex category female (1 point)",
    "DOACs include: dabigatran, rivaroxaban, apixaban, edoxaban",
    "Consider HAS-BLED score to assess bleeding risk before initiating anticoagulation"
  ]
}
